CERo Therapeutics names new CFO and CDO, reprices options to $0.10

CERO THERAPEUTICS HOLDINGS, INC.

Al Kucharchuk appointed CFO effective Oct 1, 2024; receives 500K stock options vesting over 12 months, monthly consulting fee $16K.
Kristen Pierce appointed CDO effective Oct 1, 2024; receives 200K options vesting over 24 months (50% accelerated on FDA IND acceptance), $30K/mo fee.
Chris Ehrlich named Interim CEO; receives 2.8M options vesting 50% on IND and 50% on $1.5M financing, $30K/mo fee.
All outstanding options with exercise price >$0.10 repriced to $0.10 per share under 2024 Equity Incentive Plan.
Brian Atwood (ex-CEO) and Charles Carter (ex-CFO) enter consulting agreements; Atwood forfeits 1.33M options, Carter forfeits 495K options.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Charles R. Carter

Chief Financial Officer

CERO · CERO THERAPEUTICS HOLDINGS, INC.

Effective: 2024-09-30
Successor: Andrew Albert "Al" Kucharchuk
Filed: October 2, 2024, 7:59 PM ET

As previously announced, Charles R. Carter resigned from his position as Chief Financial Officer, effective on September 30, 2024.

Appointed

Andrew Albert "Al" Kucharchuk

Chief Financial Officer

CERO · CERO THERAPEUTICS HOLDINGS, INC.

Effective: 2024-10-01
Filed: October 2, 2024, 7:59 PM ET

On September 30, 2024, the Board appointed Andrew Albert “Al” Kucharchuk as Chief Financial Officer of the Company, effective October 1, 2024.

Appointed

Kristen Pierce

Chief Development Officer

CERO · CERO THERAPEUTICS HOLDINGS, INC.

Effective: 2024-10-01
Filed: October 2, 2024, 7:59 PM ET

On September 30, 2024, the Board of Directors (the “ Board ”) of CERo Therapeutics Holdings, Inc. (the “ Company ”) appointed Kristen Pierce, Ph.D., as Chief Development Officer of the Company, effective October 1, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Charles R. Carter resigned as Chief Financial Officer at CERO THERAPEUTICS HOLDINGS, INC..

Action: resigned
Role: Chief Financial Officer

Exact text from the filing

As previously announced, Charles R. Carter resigned from his position as Chief Financial Officer, effective on September 30, 2024.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Andrew Albert "Al" Kucharchuk was appointed as Chief Financial Officer at CERO THERAPEUTICS HOLDINGS, INC..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

On September 30, 2024, the Board appointed Andrew Albert “Al” Kucharchuk as Chief Financial Officer of the Company, effective October 1, 2024.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Kristen Pierce was appointed as Chief Development Officer at CERO THERAPEUTICS HOLDINGS, INC..

Action: appointed
Role: Chief Development Officer

Exact text from the filing

On September 30, 2024, the Board of Directors (the “ Board ”) of CERo Therapeutics Holdings, Inc. (the “ Company ”) appointed Kristen Pierce, Ph.D., as Chief Development Officer of the Company, effective October 1, 2024.

View on SEC.gov

CERO THERAPEUTICS HOLDINGS, INC. filing history →

Source: SEC EDGAR

accession 0001213900-24-084337

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.